Acknowledgements We thank all participants who took part in the trial and dedicated their time and effort to attending visits, some traveling very long distances
FDA Approval for Non-Diabetics: Currently, the FDA has not approved Ozempic for obesity, although some healthcare providers may prescribe it off-label for this use
The extensive SUSTAIN and STEP clinical trial programmes, which evaluated semaglutide's safety and efficacy, have not shown a signal for increased incidence of gastrointestinal bleeding compared to placebo or active comparators, as documented in the European Medicines Agency's European Public Assessment Report (EPAR)
Many states set two to three years for product injury claims, though some states allow more or less time
Quick Answer: Unopened semaglutide remains stable until the printed expiration date when refrigerated, while opened Ozempic pens are effective for 56 days after first use
The duration of semaglutide treatment for weight loss varies based on individual goals and responses